About theriva biologics - TOVX
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.
TOVX At a Glance
Theriva Biologics, Inc.
9605 Medical Center Drive
Rockville, Maryland 20850
| Phone | 1-301-417-4364 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -25,653,000.00 | |
| Sector | Health Technology | Employees | 22 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
TOVX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.255 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.413 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.204 |
TOVX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,166,045.455 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
TOVX Liquidity
| Current Ratio | 2.146 |
| Quick Ratio | 2.146 |
| Cash Ratio | 1.531 |
TOVX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -51.333 |
| Return on Equity | -87.309 |
| Return on Total Capital | -124.336 |
| Return on Invested Capital | -83.652 |
TOVX Capital Structure
| Total Debt to Total Equity | 8.208 |
| Total Debt to Total Capital | 7.585 |
| Total Debt to Total Assets | 3.938 |
| Long-Term Debt to Equity | 5.061 |
| Long-Term Debt to Total Capital | 4.677 |